APG Asset Management N.V. Boosts Position in DexCom, Inc. (NASDAQ:DXCM)

APG Asset Management N.V. raised its position in DexCom, Inc. (NASDAQ:DXCM) by 5.9% during the second quarter, Holdings Channel reports. The fund owned 309,500 shares of the medical device company’s stock after acquiring an additional 17,302 shares during the period. APG Asset Management N.V.’s holdings in DexCom were worth $32,742,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom during the 2nd quarter valued at about $25,000. Sachetta LLC grew its position in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the period. Crewe Advisors LLC bought a new stake in DexCom during the first quarter valued at approximately $29,000. Riverview Trust Co purchased a new stake in DexCom during the first quarter valued at approximately $32,000. Finally, DT Investment Partners LLC raised its position in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DXCM. Barclays decreased their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. JPMorgan Chase & Co. downgraded DexCom from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $145.00 to $75.00 in a research note on Friday, July 26th. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Tuesday. BTIG Research dropped their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, UBS Group decreased their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Six investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $112.25.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,824 shares of company stock worth $126,390. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Down 0.4 %

NASDAQ DXCM opened at $67.29 on Friday. The stock has a 50 day moving average price of $74.55 and a 200-day moving average price of $107.88. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The company has a market capitalization of $26.76 billion, a P/E ratio of 43.86, a P/E/G ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the business earned $0.34 earnings per share. DexCom’s quarterly revenue was up 15.3% compared to the same quarter last year. As a group, equities analysts predict that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.